Front. Cardiovasc. Med.Frontiers in Cardiovascular MedicineFront. Cardiovasc. Med.2297-055XFrontiers Media S.A.10.3389/fcvm.2023.1205721Cardiovascular MedicineCorrectionCorrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in ChinaJiangYaohuiXieJun*Department Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Approved by: Frontiers in Cardiovascular Medicine, Frontiers Media SA, Switzerland
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
empagliflozinheart failure with preserved ejection fractioncost-effectiveness analysisChinapharmaco economicsection-at-acceptanceHeart Failure and TransplantationA Corrigendum on Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China by Jiang Y and Xie J. (2022) Front. Cardiovasc. Med. 9:946399. doi: 10.3389/fcvm.2022.946399
In the published article, there was an error in the affiliation. Instead of “Department of Cardiology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China”, it should be “Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.